The good and evil of complement activation in HIV-1 infection
- PMID: 20228834
- PMCID: PMC4002684
- DOI: 10.1038/cmi.2010.8
The good and evil of complement activation in HIV-1 infection
Abstract
The complement system, a key component of innate immunity, is a first-line defender against foreign pathogens such as HIV-1. The role of the complement system in HIV-1 pathogenesis appears to be multifaceted. Although the complement system plays critical roles in clearing and neutralizing HIV-1 virions, it also represents a critical factor for the spread and maintenance of the virus in the infected host. In addition, complement regulators such as human CD59 present in the envelope of HIV-1 prevent complement-mediated lysis of HIV-1. Some novel approaches are proposed to combat HIV-1 infection through the enhancement of antibody-dependent complement activity against HIV-1. In this paper, we will review these diverse roles of complement in HIV-1 infection.
Similar articles
-
Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.J Virol. 2015 Sep;89(18):9393-406. doi: 10.1128/JVI.01614-15. Epub 2015 Jul 1. J Virol. 2015. PMID: 26136568 Free PMC article.
-
Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.J Immunol. 2014 Oct 1;193(7):3577-89. doi: 10.4049/jimmunol.1303030. Epub 2014 Aug 22. J Immunol. 2014. PMID: 25149467 Free PMC article. Clinical Trial.
-
Humoral immunity to HIV-1: neutralization and beyond.J Intern Med. 2007 Jul;262(1):5-25. doi: 10.1111/j.1365-2796.2007.01819.x. J Intern Med. 2007. PMID: 17598812 Review.
-
A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement.Virol J. 2010 Jun 29;7:142. doi: 10.1186/1743-422X-7-142. Virol J. 2010. PMID: 20584336 Free PMC article.
-
HIV and human complement: mechanisms of interaction and biological implication.Immunol Today. 1993 Sep;14(9):435-40. doi: 10.1016/0167-5699(93)90246-H. Immunol Today. 1993. PMID: 8216721 Review.
Cited by
-
The complement system in preeclampsia: a review of its activation and endothelial injury in the triad of COVID-19 infection and HIV-associated preeclampsia.Obstet Gynecol Sci. 2023 Jul;66(4):253-269. doi: 10.5468/ogs.22175. Epub 2023 Jan 4. Obstet Gynecol Sci. 2023. PMID: 36597584 Free PMC article.
-
Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitution.Clin Exp Immunol. 2019 Dec;198(3):359-366. doi: 10.1111/cei.13366. Epub 2019 Sep 8. Clin Exp Immunol. 2019. PMID: 31461782 Free PMC article.
-
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.PLoS One. 2017 Jul 5;12(7):e0180720. doi: 10.1371/journal.pone.0180720. eCollection 2017. PLoS One. 2017. PMID: 28678869 Free PMC article.
-
C-Type Lectin Receptors in Antiviral Immunity and Viral Escape.Front Immunol. 2018 Mar 26;9:590. doi: 10.3389/fimmu.2018.00590. eCollection 2018. Front Immunol. 2018. PMID: 29632536 Free PMC article. Review.
-
Enhanced complement activation and MAC formation accelerates severe COVID-19.Cell Mol Life Sci. 2024 Sep 16;81(1):405. doi: 10.1007/s00018-024-05430-w. Cell Mol Life Sci. 2024. PMID: 39284944 Free PMC article.
References
-
- Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol. 2006;3:333–340. - PubMed
-
- Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist. 2008;13:954–966. - PubMed
-
- Morgan BP, Berg CW, Harris CL. “Homologous restriction” in complement lysis: roles of membrane complement regulators. Xenotransplantation. 2005;12:258–265. - PubMed
-
- Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol. 1999;19:173–198. - PubMed
-
- Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058–1066. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous